Dr. Marty Makary Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Re: Support for FDA Action to Address Unapproved and Misleading Compounded GLP-1 Drugs Dear Commissioner Makary: We write to applaud the FDA’s February 6, 2026 announcement to take decisive action against mass-marketed, non-FDA-approved GLP-1 drugs that put patients at risk. The Agency’s clear signal that it intends to use its enforcement authority was a welcome development in the face of so many flagrant violations by compounders. Your statement reinforces a foundational principle: companies may not mass-produce and mass-market, either online or in-person, [...]